5-Hydroxymethylcytosine

5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes)^[1][2]. In Vitro:5-Hydroxymethylcytosine (5hmC) is a stable epigenetic modification derived from the oxidation of 5-methylcytosine (5mC) by ten-eleven translocation (TET) enzymes (TET1, TET2, TET3). 5-Hydroxymethylcytosine functions as both an intermediate in active DNA demethylation and an independent regulator of gene expression-enriching in CpG islands, active/bivalent promoters, and transcriptional enhancers to promote euchromatin formation and modulate transcription factor binding. 5-Hydroxymethylcytosine plays pivotal roles in biological processes: maintaining embryonic stem cell (ESC) pluripotency, driving neurodevelopment, and restraining tumor progression^[2].